Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer

Published:2021-10 Issue:10 Volume:39 Page:728.e13-728.e24
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Csizmarik Anita,Hadaschik Boris,Kramer Gero,Nyirady Peter,Szarvas Tibor

Funder

Ministry for Innovation and Technology

National Research, Development and Innovation Office

Magyar Tudományos Akadémia

Nemzeti Kutatási, Fejlesztési és Innovaciós Alap

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference60 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

3. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

4. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

5. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PROTACing the androgen receptor and other emerging therapeutics in prostate cancer;Expert Review of Anticancer Therapy;2024-07-22

2. Purine-Rich Element Binding Protein Alpha, a Nuclear Matrix Protein, Has a Role in Prostate Cancer Progression;International Journal of Molecular Sciences;2024-06-24

3. MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products;Aging and disease;2024

4. Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2023-08-26

5. Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer;Cancer Reports;2022-12-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3